The relationship of depression to cardiovascular disease: Epidemiology, biology, and treatment

Archives of General Psychiatry

Volumn 55, Issue 7, 1998, Pages 580-592

  Musselman, Dominique L ^a   Evans, Dwight L ^b   Nemeroff, Chartes B ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; MONOAMINE OXIDASE INHIBITOR; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; THROMBOCYTE RECEPTOR; TRICYCLIC ANTIDEPRESSANT AGENT;

CARDIOVASCULAR DISEASE; DEATH; DEPRESSION; HEART INFARCTION; HEART RATE VARIABILITY; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; ISCHEMIC HEART DISEASE; MENTAL STRESS; QUALITY OF LIFE; REVIEW; RISK FACTOR; SYMPATHETIC INNERVATION;

EID: 0031822289     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.55.7.580     Document Type: Review

References (195)

1. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey, Arch Gen Psychiatry. 1994:51:8-19.
2. Hoeper EW, Nycz GR, Cleary PD. Estimated prevalence of RDC mental disorders in primary care. Int J Ment Health. 1979:8:6-15.
3. Leeper J, Badger L, Milo T, Mental disorders among physical disability determination patients. Am J Public Health, 1985:75:78-79.
4. Blacker CVR, Clare AW. Depressive disorder in primary care. Br J Psychiatry. 1987:150:737-751.
5. Barrett JE, Barrett JA, Oxman TE, Gerber PD. The prevalence of psychiatric disorders in a primary care practice. Arch Gen Psychiatry. 1988;45:1100-1106.
6. Von Korff M, Shapiro S, Burke JD, Teitlebaum M, Skinner EA, German P, Turner RW, Klein L, Burns B. Anxiety and depression in a primary care clinic: comparison of Diagnostic Interview Schedule, General Health Questionnaire, and practitioner assessments. Arch Gen Psychiatry. 1987;44:152-156.
7. Cohen-Cole SA, Kaufman KG. Major depression in physical illness: diagnosis, prevalence, and antidepressant treatment (a ten-year review; 1982-1992). Depression. 1993;1:181-204.
8. Magni G, Schifano F, DeLeo D, Assessment of depression in an elderly medical population. J Affect Disord. 1986;11:121-124.
9. Feldman E, Mayou R, Hawton K, Ardern M, Smith EB. Psychiatric disorder in medical inpatients. QJM 1987;63:405-412.
10. Boyd JH, Weissman MM. Epidemiology of affective disorders. Arch Gen Psychiatry. 1981;38:1039-1046.
11. Blazer D, Swartz M, Woodbury M, Manton KG, Hughes D, George LK. Depressive symptoms and depressive diagnoses in a community population; use of a new procedure for analysis of psychiatric classification. Arch Gen Psychiatry. 1988;45:1078-1084.
12. Bebbington P, Katz R, McGuffin P, Tennant C, Hurry J. The risk of minor depression before age 65: results from a community survey. Psychol Med. 1989;19:393-400.
13. Broadhead WE, Blazer DG, George LK, Tse CK. Depression, disability days, and days lost from work in a prospective epidemiologic survey, JAMA. 1990;264:2524-2528.
14. Johnson J, Weissman MM, Klerman GL. Service utilization and social morbidity associated with depressive symptoms in the community. JAMA 1992;267:1478-1483.
15. Shepherd M, Cooper B, Brown AC, Kalton GW. Psychiatric illness in General Practice. London, England: Oxford University Press; 1966.
16. Kessler LG, Cleary PD, Burke JD Jr. Psychiatric disorders in primary care: results of a follow-up study. Arch Gen Psychiatry. 1985;42:583-587.
17. Ormel J, Koeter MWJ, van den Brink W, van de Willige G. Recognition, management, and course of anxiety and depression in general practice. Arch Gen Psychiatry. 1991;48:700-706.
18. Kurosawa H, Shimizu Y, Nishimatsu Y, Hirose S, Takano T. The relationship between mental disorders and physical severities in patients with acute myocardiat infarction. Jpn Circ J. 1983;47:723-725.
19. Wynn A. Unwarranted emotional distress in men with ischaemic heart disease. Med J Aust. 1967;2:847-851.
20. Mayou R, Foster A, Williamson B. Medical care after myocardial infarction. J Psychosom Res. 1979;23:23-26.
21. Carney RM, Rich MW, teVelde A, Saini J, Clark K, Jaffe AS. Major depressive disorder in coronary artery disease. Am J Cardiol. 1987;60: 1273-1275.
22. Schleifer SJ, Macari-Hinson MM, Coyle DA, Slater WR, Kahn M, Gorlin R, Zucker HD. The nature and course of depression following myocardial infarction. Arch Intern Med. 1989;149:1785-1789.
23. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction: impact on 6-month survival. JAMA. 1993;270: 1819-1861.
24. Blumenthal JA, Williams RS, Wallace AG, Williams RB, Needles TL. Physiological and psychological variables predict compliance to prescribed exercise therapy in patients recovering from myocardial infarction. Psychosom Med. 1982;44:519-527.
25. Stern JJ, Pascale L, Ackerman A. Life adjustment post myocardial infarction: determine predictive variables. Arch Intern Med. 1977;137: 1680-1685.
26. Mayou R, Foster A, Williamson B. Psychosocial adjustment in patients one year after myocardial infarction. J Psychosom Res. 1978;22:447-453.
27. Skodol AE, Schwartz S, Dohrenwend BP, Levav I, Shrout PE. Minor depression in a cohort of young adults in Israel. Arch Gen Psychiatry, 1994;51: 542-551.
28. Wells KB, Stewart A, Hayes RD, Burnam MA, Rogers W, Daniels M, Berry S, Greenfield S, Ware J. The functioning and well-being of depressed patients: results of the Medical Outcomes Study. JAMA. 1989;262:914-919.
29. Carney RM, Rich MW, Freedland KE, Saini J. Major depressive disorder predicts cardiac events in patients with coronary artery disease. Psychosom Med. 1988;50:627-633.
30. Aromaa A, Raitasalo R, Reunanen A, Impivaara O, Heliovaara M, Kneckt P, Lehtinen V, Joukamaa M, Maatela J. Depression and cardiovascular diseases. Acta Psychiatr Scand. 1994;377: 77-82.
31. Ahern DK, Gorkin L, Anderson JL, Tierney C, Hallstrom A, Ewart C, Capone RJ, Schron E, Kornfeld D, Herd JA, Richardson DW, Follick MJ, for the CAPS Investigators. Biobehavioral variables and mortality or cardiac arrest in the Cardiac Arrhythmia Pilot Study (CAPS). Am J Cardiol. 1990;66:59-62.
32. Frasure-Smith N, Lesperance F, Talajic M, Depression and 18-month prognosis after myocardial infarction. Circulation. 1995;91:999-1005.
33. Hackett TP, Cassem, NH, Wishnie HA. The coronary-care unit: an appraisal of its psychologic hazards. N Engl J Med. 1968;279:1365-1370.
34. Cay EL, Vetter N, Philip AE, Dugard P. Psychological status during recovery from an acute heart attack. J Psychosom Res. 1972;16:425-435.
35. Robins LN, Helzer JE, Croughan JL, Williams JBW, Spitzer RL. The NIMH Diagnostic Interview Schedule, Version III. Public Health Service (HSS), ADM-T-42-3 (5-81, 8-81). Washington DC; 1981.
36. Endicott J, Spitzer RL. A diagnostic interview: the Schedule for Affective Disorders and Schizophrenia. Arch Gen Psychiatry. 1978;35:837-844.
37. Gonzalez MB, Snyderman TB, Colket JT, Arias RM, Jiang JW, O'Connor CM, Krishnan KR. Depression in patients with coronary artery disease. Depression. 1996;4:57-62.
38. Hayward C. Psychiatric illness and cardiovascular disease risk. Epidemiol Rev. 1995;17: 129-138.
39. Ostfeld AM, Lebovits BZ, Shekelle RB, Paul O. A prospective study of the relationship between personality and coronary heart disease. J Chronic Dis. 1964;17:265-276.
40. Hathaway SR, McKinley JC. Minnesota Multiphasic Personality Inventory Manual (Revised Edition). New York, NY: The Psychological Corporation; 1951.
41. Cattall, RB, Saunders DR, Stice G. Handbook for the Sixteen Personality Factor Questionnaire. Champaign, III: Institute for Personality and Ability Testing; 1957.
42. Brozek J, Keyes A, Blackburn H. Personality differences between potential coronary and noncoronary subjects, Ann NY Acad Sci. 1966;134: 1057-1064.
43. Dahlstrom WG, Welsh GS. A MMPI Handbook: A Guide to Use in Clinical Practice and Research. Minneapolis, Minn: University of Minnesota Press; 1960.
44. Goldberg EL, Comstock GW, Hornstra RK. Depressed mood and subsequent physical illness. Am J Psychiatry. 1979;136:530-534.
45. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. J Applied Psychol Meas. 1977;1:385-401.
46. Murphy JM, Monson RR, Olivier DC, Sobol AM, Leighton AH. Affective disorders and mortality. Arch Gen Psychiatry. 1987;44:473-480.
47. Murphy JM, Neff RK, Sobol AM, Rice JX, Olivier DC. Computer diagnosis of depression and anxiety: the Stirling County Study. Psychol Med. 1985;15:99-112.
48. Anda R, Williamson D, Jones D, Macera C, Eaker E, Glassman A, Marks J. Depressed affect, hopelessness, and the risk of ischemie heart disease in a cohort of U.S. adults. Epidemiology. 1993;4:285-294.
49. Dupuy HJ. A concurrent validational study of the NCHS General Well-Being Schedule. Vital Health Stat. 1977; No. 73.
50. Wing JK, Cooper JE, Sartorius N. The measurement and classification of psychiatric symptoms. London, England: Cambridge University Press; 1974.
51. Ford DE, Mead LA, Chang PP, Levine DM, Klag MJ. Depression predicts cardiovascular disease in men: the Precursors Study [abstract]. Circulation. 1994;90(Suppl I):614.
52. Vogt T, Pope C, Mullooly J, Hollis J, Mental heath status as a predictor of morbidity and mortality: a 15-year follow-up of members of a health maintenance organization. Am J Public Health. 1994;84:227-231.
53. McFarland BH, Freeborn DK, Mullooly JP, Pope CR. Utilization patterns among long-term enrollees in a prepaid group practice health maintenance organization. Med Care. 1985;23: 1221-1233.
54. Simonsick EM, Wallace RB, Blazer DG, Berkman LF. Depressive symptomatology and hypertension-associated morbidity and mortality in older adults. Psychosom Med. 1995;57: 427-435.
55. Everson SA, Goldberg DE, Kaplan GA, Cohen RD, Pukkala E, Tuomilehto J, Salonen JT. Hopelessness and risk of mortality and incidence of myocardial infarction and cancer. Psychosom Med. 1996;58:113-121.
56. Barefoot JC, Schroll M. Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. Circulation. 1996;93:1976-1980.
57. Greene RL. The MMPI-2/MMPI: An interpretive Manual. Boston, Mass: Allyn and Bacon; 1991.
58. Pratt LA, Ford DE, Crum RM, Armenian HK, Gallo JJ, Eaton WW. Depression, psychotropic medication, and risk of myocardial infarction: prospective data from the Baltimore EGA followup. Circulation. 1996;94:3123-3129.
59. Wassertheil-Smoller S, Applegate WB, Berge K, Chang CJ, Davis BR, Grimm R, Kostis J, Pressel S, Schron E, for the SHEP Cooperative Research Group. Change in depression as a precursor of cardiovascular events. Arch intern Med. 1996;156:553-561.
60. Berkman LF, Berkman CS, Kasl S, Freeman DH Jr, Ostfeld AM, Cornoni-Huntley J, Brody JA. Depressive symptoms in relation to physical health and functioning in the elderly. Am J Epidemiol. 1986;124:372-388.
61. Musselman DL, Knight BT, Baron A, Nemeroff CB. Further studies on altered platelet reactivity in major depression. Presented at Society of Biological Psychiatry Annual Meeting, May 27-31, 1998, Toronto, Canada.
62. Vingerhoets A. Psychosocial Stress: An Experimental Approach. Groningen, the Netherlands: Swets & Zeitlinger;1985.
63. Selye H. The Stress of Life. New York, NY: McGraw-Hill;1956.
64. Nemeroff CB, Widerlov E, Bissette G, Walleus H, Karlsson I, Eklund K, Kilts CD, Loosen PT, Vale W. Elevated concentrations of CSF corticotropinreleasing factor-like immunoreactivity in depressed patients. Science. 1984;226:1342-1344.
65. Arato M, Banki CM, Nemeroff CB, Bissette G, Hypothalamic-pituitary-adrenal axis and suicide. Ann N Y Acad Sci. 1986;487:263-270.
66. Banki CM, Bissette G, Arato M, O'Connor L. Nemeroff CB, Cerebrospinal fluid corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia. Am J Psychiatry, 1987;144:873-877.
67. Banki CM, Karmasci L, Bissette G, Nemeroff CB. CSF corticotropin-releasing and somatostatin in major depression: response to antidepressant treatment and relapse. Eur Neuropsychopharmacol. 1992;2:107-113.
68. France RD, Urban B, Krishnan KRR, Bissett G, Banki CM, Nemeroff C, Speilman FJ. CSF corticotropin-releasing factor-like immunoreactivity in chronic pain patients with and without major depression. Biol Psychiatry. 1988;23:86-88.
69. Risch SC, Lewine RJ, Kalin NH, Jewart RD, Risby ED, Caudle JM, Stipetic M, Turner J, Eccard MB, Pollard WE, Limbic-hypothalamic-pituitary-adrenal axis activity and ventricular-to-brain ratio studies in affective illness and schizophrenia. Neuropsychopharmacology. 1992;6:95-100.
70. Raadsheer FC, Hoogendijk WJG, Stam FC, Tilders FJH, Swaab DF. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology. 1994;60:436-444.
71. Raadsheer FC, van Heerikhuize JJ, Lucassen PJ, Hoogendijk WJG, Tilders FJH, Swaab DF. Corticotropin-releasing hormone mRNA levels in the paraventricular nucleus of patients with Alzheimer's disease and depression. Am J Psychiatry. 1995;152:1372-1376.
72. Bjorkerud S. Effect of adrenocortical hormones on the integrity of rat aortic endothelium. In: Schettler G, and Weizel A, eds. Proceedings of the 3rd International Symposium on Atherosclerosis. Berlin, Germany: Springer-Verlag; 1973:245.
73. Nahas GG, Brunson JG, King WM, Cavert HM. Functional and morphologic changes in heart lung preparations following administration of adrenal hormones. Am J Clin Pathol. 1958;34: 717-729.
74. ValigorskyJM. Metaplastic transformation oi aortic smooth muscle cells in cortisone-induced dissecting aneurysms in hamsters. Fed Proc. 1969;28:802.
75. Kemper JW, Baggenstoss AH, Slocumb CH. The relationship of therapy with cortisone to the incidence of vascular lesions in rheumatoid arthritis. Ann Intern Med. 1957;46:831-851.
76. Ross R, Harker L. Hyperlipidemia and atherosclerosis. Science. 1976;193:1094-1100.
77. Troxler RG, Sprague EA, Albanese RA, Fuchs R, Thompson AJ. The association of elevated plasma cortisol and early atherosclerosis as demonstrated by coronary angiography. Atherosclerosis. 1977;26:151-162.
78. Swanson LW, Sawchenko PE. Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinology. 1983;36:165-186.
79. Merchenthaler I, Vigh S, Petruscz P, Schally AV. Immunocytochemical localization of corticotropin-releasing factor (CRF) in the rat brain. Am J Anatomy. 1982;165:385-396.
80. Cummings S, Eide R, Ellis J, Lindall A. Corticotropin-releasing factor immunoreactivity is widely distributed with the central nervous system of the rat: an immunonistochemical study. J Neurosci. 1983;8:1355-1368.
81. Wyatt RJ, Portnoy B, Kupfer DJ, Snyder F, Engelman K. Resting plasma catecholamine concentrations in patients with depression and anxiety. Arch Gen Psychiatry. 1971;24:65-70.
82. Louis WJ, Doyle AE, Anavekar SN. Plasma noradrenaline concentration and blood pressure in essential hypertension, phaeochromocytoma and depression. Clin Soc. 1975;48:239S-242S.
83. Roy A, Pickar D, DeJong J, Karoum F, Linnoila M. Norepinephrine and its metabolites in cerebrospinal fluid, plasma, and urine: relationship to hypothalamic-pituitary-adrenal axis function in depression. Arch Gen Psychiatry. 1988;45: 849-857.
84. Veith RC, Lewis L, Linares OA, Barnes RF, Raskin MA, Villacres EC, Murburg MM, Ashleigh EA, Castillo S, Peskind ER, Pascualy M, Halter JB. Sympathetic nervous system activity in major depression: basal and desipramine-induced alterations in plasma norepinephrine kinetics. Arch Gen Psychiatry. 1994;51:411-422.
85. Roy A, Guthrie S, Pickar D, Linnoila M. Plasma WE responses to cold challenge in depressed patients and normal controls. Psychiatry Res. 1987;21:161-168.
86. Charney DS, Menkes DB, Henninger GR. Receptor sensitivity and the mechanism of action of antidepressant treatment. Arch Gen Psychiatry. 1981;38:1160-1180.
87. Golden RN, Markey SP, Risby ED, Rudorfer MV, Cowdry RW, Potter WZ. Antidepressants reduce whole-body norepinephrine turnover while enhancing 6-hydroxymelatonin output. Arch Gen Psychiatry. 1988;45:150-154.
88. Linnoila M, Karoum F, Calil HM, Kopin IJ, Potter WZ. Alteration of NE metabolism with desipramine and zimelidine in depressed patients. Arch Gen Psychiatry. 1982;39:1025-1028.
89. Linnoila M, Guthrie S, Lane EA, Karoum F, Rudorter M, Potter WZ. Clinical studies on NE metabolism: how to interpret the numbers. Psychiatry Res. 1986;17:229-239.
90. Scubee-Moreau JJ, Dresse AE. Effect of various antidepressant drugs on the spontaneous firing rate of locus coeruleus and raphe dorsalis neurons of the rat. Eur J Pharmacol. 1979;57:219-225.
91. Sulser F, Vetulani J, Mobley PL. Mode of action on antidepressant drugs. Biochem Pharmacol. 1978;27:257-261.
92. Anfossi G, Trovati M. Role of catecholamines in platelet function: pathophysiological and clinical significance. Eur J Clin Invest. 1996;26:353-370.
93. Gerritsen ME. Physiological and pathophysiological roles of eicosanoids in the microcirculation. Cardiovasc Res. 1996;32:720-732.
94. Goldstein DS. Plasma catecholamines and essential hypertension; an analytical review. Hypertension. 1983;5:86-99.
95. Lund-Johansen P. Hemodynamic alterations in early essential hypertension: recent advances. In: Gross F, Strasser T, eds. Mild Hypertension: Recent Advances. New York, NY: Raven Press; 1983;237-249.
96. Lechin F, van der Dijs B, Orozco B, Lechin ME, Baez S, Lechin AE, Rada I, Acosta E, Arocha L, Jimenez V, Leon G, Garcia Z. Plasma neurotransmitters, blood pressure, and heart rate during supine-resting, orthostasis, and moderate exercise conditions in major depressed patients. Biol Psychiatry. 1995;38:166-173.
97. Akselrod S, Gordon D, Ubel FA, Shannon DC, Barger AC, Cohen RJ. Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control. Science. 1981;213:220-222.
98. Low PA. Autonomic nervous system function. J Clin Neurophysiol. 1993;10:14-27.
99. Spyer KM. Central nervous system control of the cardiovascular system. In: Bannister, R, ed. Autonomic Failure: A Textbook of Clinical Disorders of the Autonomic Nervous System. Oxford, England: Oxford University Press; 1988:56-79.
100. Shields RW. Functional anatomy of the autonomic nervous system. J Clin Neurophysiol. 1993;10:2-13.
101. Dalack GW, Roose SP. Perspectives on the relationship between cardiovascular disease and affective disorder. J Clin Psychiatry. 1990;51 (suppl):4-9.
102. Wolf M, Varigos G, Hunt D, Sloman JG. Sinus arrhythmia in acute myocardial infarction. Med J Aust. 1978;2:52-53.
103. Billman GE, Schwartz PJ, Stone HL. Baroreceptor reflex control of heart rate: a predictor of sudden cardiac death. Circulation. 1982;66:874-880.
104. Kleiger RE, Miller PJ, Bigger TJ, Moss AJ, and the Multicenter Post-Infarction Research Group. Decreased heart rale variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol. 1987;59: 256-262.
105. Bigger JT, Kleiger RE, Fleiss JL, Rolnitzky LM, Steinman RC, Miller JP. Components of HR variability measured during healing of acute myocardial infarction. Am J Cardiol. 1988;61: 208-215.
106. LaRovere MT, Specchia G, Mortana A, Schwartz PJ. Baroreflex sensitivity, clinical correlates, and cardiovascular mortality among patients with a first myocardial infarction: a prospective study. Circulation. 1988;78:816-824.
107. Cripps T, Malik M, Farrell T, Camm AJ. Prognostic value of reduced heart rate variability after myocardial infarction: clinical evaluation of a new analysis method. Br Heart J. 1991;65: 14-19.
108. Viskin S, Belhassen B. Noninvasive and invasive strategies for the prevention of sudden death after myocardial infarction: value, limitations and implications for therapy. Drugs. 1992;44: 336-355.
109. Araya-Gomez V, Gonzalez-Hermosillo J, Casanova-Garces J, Colin L, Kershenovich S, Iturralde P. Identification of patients at risk of malignant arrythmia in the 1st year after myocardial infarction [in Spanish]. Arch Inst Cardiol Mex. 1994;64:145-159.
110. Campbell RWF. Can analysis of heart rate variability predict arrhythmias and antiarrhythmic effects? In: Oto AM, ed. Practice and Progress in Cardiac Pacing and Electrophysiology. Dordrecht, the Netherlands: Kluwer Academic Publishers; 1996:63-69.
111. Sayers BM. Analysis of heart rate variability. Ergonomics. 1973;16:17-32.
112. Pomeranz B, Macaulay RJB, Caudill MA, Kutz I, Adam D, Gordon D, Kilborn KM, Barger AC, Shannon DC, Cohen RJ, Benson H. Assessment of autonomic function in humans by heart rate spectral analysis. Am J Physiol. 1985;248: H151-H153.
113. Pagani M, Lombardi F, Guzzetti S, Rimoldi O, Furlan R, Pizzinelli P, Sandrone G, Malfatto G, Dell'Orto S, Piccaluga E, Turiel M, Baselli G, Cerutti S, Malliani A. Power spectral analysis of heart rate and arterial pressure variabilities as a marker of sympathovagal interaction in man and conscious dog. Circ Res. 1986;59: 178-193.
114. Koizumi K, Terui N, Kollai M. Effect of cardiac vagal and sympathetic nerve activity on heart rate in rhythmic fluctuations. J Autonom Nerv Syst. 1985;12:251-259.
115. Katona PG, Jih F. Respiratory sinus arrhythmia: noninvasive measure ot the parasympathetic cardiac control. J Appl Physiol. 1975;39:801-805.
116. Fouad FM, Tarazzi RC, Gerrario CM, Fighaly S, Alicandri C. Assessment of parasympathetic control of heart rate by a noninvasive method. Am J Physiol. 1984; 246:H838-842.
117. Bigger TJ Jr, Fleiss JL, Steinman RC, Rolnitzky LM, Kleiger RE, Rottman JN. Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation. 1992;85:164-171.
118. Miyawaki E, Salzman C, Autonomic nervous system tests in psychiatry: implications and potential uses of heart rate variability. Integrated Psychiatry. 1991;7:21-28.
119. Rechlin T, Weis M, Claus D. Heart rate variability in depressed patients and differential effects of paroxetine and amitriptyline on cardiovascular autonomic functions. Pharmacopsychiatry. 1994;27:124-128.
120. Yeragani VK, Pohl R, Ramesh C, Glitz D, Weinberg P, Merlos B. Effect of imipramine treatment on heart rate variability measures. Neuro-psychobiology. 1992;26:27-32.
121. Carney RM, Saunders RD, Freedland KE, Stein P, Rich MW, Jaffe AS. Association of depression with reduced heart rate variability in coronary artery disease. Am J Cardiol. 1995;76: 562-564.
122. Roose SP, Glassman AH, Dalack GW. Depression, heart disease, and tricyclic antidepressants. J Clin Psychiatry, 1989;50(suppl 7):12-16.
123. Balogh S, Fitzpatrick DF, Hendricks SE, Paige SR. Increases in heart rate variability with successful treatment in patients with major depressive disorder. Psychopharmacol Bull. 1993;29: 201-206.
124. Verrier RL. Behavioral stress, myocardial ischemia, and arrhthmias. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology From Cell to Bedside. Philadelphia, Pa: WB Saunders Co; 1990:343-352.
125. Jiang W, Babyak M, Krantz DS, Waugh RA, Coleman RE, Hanson MM, Frid DJ, McNulty S, Morris JJ, O'Connor CM, Blumenthal JA. Mental stress-induced myocardial ischemia and cardiac events. JAMA. 1996;21:1651-1656.
126. Lown B, DeSilva RA, Reich P, Murawski BJ. Psychophysiologic factors in sudden cardiac death. Am J Psychiatry. 1980;137:1325-1335.
127. Lown B, Verrier RL. Neural activity and ventricular fibrillation. N Engl J Med. 1976;294:1165-1170.
128. Zaza A, Schwartz PJ. Role of the autonomic nervous system in the genesis of early ischemic arrhythmias. J Cardiovasc Pharmacol. 1985;7 (suppl 5):S8-S12.
129. Stedman's Medical Dictionary. Baltimore, Md: Williams & Wilkins; 1982.
130. Heit S, Owens MJ, Plotsky P, Nemeroff CB. Corticotropin-releasing factor, stress, and depression. Neuroscientist. 1997;3:186-194.
131. Tavazzi L, Zotti AM, Rondanelli R. The role of psychologic stress in the genesis of lethal arrhythmias in patients with coronary artery disease. Eur Heart J. 1986;7(suppl):99-106.
132. Follick MJ, Gorkin L, Capone RJ, Smith TW, Ahern DK, Stablein D, Niaura R, Visco J. Psychological distress as a predictor of ventricular arrhthmias in a post-myocardial infarction population. Am Heart J. 1988;116:32-36.
133. Gold PW, Gooodwin FK, Chrousos GP, Clinical and biochemical manifestations of depression: relation to the neurobiology of stress. N Engl J Med. 1988;319:413-420.
134. Valentino RJ, Foote SL, Page ME. The locus coeruleus as a site for integrating corticotropin-releaslng factor and noradrenergic mediation of stress responses. Ann N Y Acad Sci. 1993;697: 173-188.
135. Curtis AL, Pavcovich LA, Grigoriadis DE, Valentino RJ. Previous stress alters corticotropin-releasing factor neurotransmission in the locus coeruleus. Neuroscience. 1995;65:541-550.
136. Chrousos GP, Gold PW. The concepts of stress and stress system disorders: overview of physical and behavioral homeostasis. JAMA. 1992;267:1244-1252.
137. Paykel E. Causal relationships between clinical depression and life events. In: Barrett JE, ed. Stress and Mental Disorder. New York, NY: Raven Press; 1979.
138. Kendler KS, Kessler RC, Neale MC, Heath AC, Eaves LJ. The prediction of major depression in women: toward an integrated etiologic model. Am J Psychiatry. 1993;150:1139-1148.
139. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg, D, Baker A, Friedman L, Greene HL, Huther ML, Richardson DW, and the CAST Investigators. Mortality and morbidity in patients receiving ecainide, flecenaide or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324:781-788.
140. Markovitz JH, Matthews KA. Platelets and coronary heart disease: potential psychophysiologic mechanism. Psychosom Med. 1991;53: 643-668.
141. Morris PLP, Robinson RG, Andrzejewski P, Samuels J, Price TR. Association of depression with 10-year poststroke mortality. Am J Psychiatry. 1993;150:124-129.
142. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 1995;332:1553-1559.
143. Hess H, Mietaschk A, Deichsel G. Drug-educed inhibition of platelet function delays progression of peripheral occlusive arterial disease: a prospective double-blind arteriographically controlled trial. Lancet. 1985;1:415-419.
144. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ. 1988;296:320-331.
145. Verstraete M. Risk factors, interventions and therapeutic agents in the prevention of artherosclerosis-related ischaemic diseases. Drugs. 1991;42(suppl 5):22-38.
146. Ridker PM, Manson JE, Burning JE, Goldhaber SZ, Hennekens CH. The effect of chronic platelet inhibition with low-dose aspirin on atherosclerotic progression and acute thrombosis: clinical evidence from the Physicians' Health Study. Am Heart J. 1991;122:1588-1592.
147. Musselman DL, Tomer A, Manatunga AK, Knight BT, Porter MR, Kasey S, Marzec U, Harker LA, Nemeroff CB. Exaggerated platelet reactivity in major depression. Am J Psychiatry. 1996;153: 1313-1317.
148. Laghrissi-Thode F, Wagner WR, Pollock BG, Johnson PC, Finkel MS, Elevated platelet factor 4 and β-thromboglobulin plasma levels in depressed patients with ischemic heart disease. Biol Psychiatry. 1997;42:290-295.
149. Weyrich AS, Solis GA, Li KS, Tulenko TN, Santamore WP. Platelet amplification of vasospasm. Am J Physiol. 1992;263(suppl):H349-H358.
150. DeClerck F. Effects of serotonin on platelets and blood vessels. J Cardiovasc Pharmacol. 1991;17(suppl 5):S1-S5.
151. Owens MJ, Nemeroff CB. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem. 1994;40:288-295.
152. Osim EE, Wyllie JH. Evidence for loss of 5-hydroxytryptamine from circulating platelets. J Physiol (Lond). 1982;326:25P-26P.
153. Ashton JH, Benedict CR, Fitzgerald C, Raheja S, Taylor AL, Campbell WB, Buja LM, Willerson JT. Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries. Circulation. 1986;73:572-578.
154. Ashton JH, Ogletree ML, Michel IM, Golino P, McNatt JM, Taylor AL, Raheja S, Schmitz J, Buja LM, Campell WB, Willerson JT. Cooperative mediation by serotonin S2 and thromboxane A2/ prostaglandin H2 receptor activation of cyclic flow variation in dogs with severe coronary artery stenosis. Circulation. 1987;76:952-959.
155. Biegon A, Weizman A, Karp L, Ram A, Iano S, Wolff M, Serotonin 5-HT2 receptor binding on blood platelets: a peripheral marker for depression? Life Sci. 1987;41:2485-2492.
156. Biegon A, Grinspoon A, Blumenfelt B. Bleich A, Apter A, Mester R, Increased serotonin 5-HT2 receptor binding on blood platelets in suicidal men. Psychopharmacology. 1990;100:165-167.
157. Biegon A, Essar N, Israeli M, Elizur A, Bruch S, Bar-Nathan AA. Serotonin 5-HT2 receptor binding on blood platelets as a state dependent marker in major affective disorder. Psychopharmacology. 1990;100:73-75.
158. Arora RC, Meltzer HY. Increased serotonin (5HT2) receptor binding as measured by 3H-LSD in the blood platelets of depressed patients. Life Sci. 1989;44:725-734.
159. Pandey GN, Pandey SC, Janicak PG. Platelet serotonin-2 binding sites in depression and suicide. Biol Psychiatry. 1990;28:215-222.
160. Briley MS, Langer SZ, Raisman R, Sechter D, Zarifian E. Tritiated imipramine binding sites are decreased in platelets of untreated depressed patients. Science. 1980;209:303-315.
161. Langer SZ, Arifian E, Briley MS, Raisman R, Sechter D. High-affinity binding of 3H-imipramine in brain and platelets and its relevance to the biochemistry of affective disorders. Life Sci. 1981;29:211-218.
162. Paul SM, Rehavi M, Skolnick P, Ballenger JC, Goodwin FK. Depressed patients have decreased binding of titrated imipramine to platelet serotonin "transporter." Arch Gen Psychiatry. 1981;38:1315-1317.
163. 3H]imipramine binding sites in geriatric depression. Arch Gen Psychiatry, 1988;45:919-923.
164. Nemeroff CB, Knight DL, Franks J, Craighead WE, Krishnan KRR. Further studies on platelet transporter binding in depression. Am J Psychiatry. 1994;151:1623-1625.
165. Cerrito F, Lazzaro MP, Gaudio E, Arminio P, Aloisi G, 5HT2-receptors and serotonin release: their role in human platelet aggregation. Life Sci. 1993;53:209-215.
166. Kusumi I, Koyama T, Yamashita I. Serotoninstimulated Ca2 + response is increased in the blood platelets of depressed patients. Biol Psychiatry. 1991;30:310-312.
167. 2 receptor function as measured by serotonin-stimulated phosphoinositide hydrolosis in platelets of depressed patients. Prog Neuropsychopharmacol Biol Psychiatry. 1991;15:49-61.
168. Eckert A, Gann H, Riemann D, Aldenhoff J, Muller WE, Elevated intracellular calcium levels after 5-HT2 receptor stimulation in platelets of depressed patients. Biol Psychiatry, 1993;34: 565-568.
169. Ware JA, Smith M, Salzman EW, Synergism of platelet aggregating agents: role of elevation of cytoplasmic calcium. J Clin Invest. 1987;80: 267-271.
170. Friedman M, Thoresen CE, Gill JJ, Ulmer D, Powell LH, Price VA, Brown B, Thompson L, Rabin DD, Breall WS, Bourg E, Levy R, Dixon T. Alteration of type A behavior and its effect on cardiac recurrences in post myocardial infarction patients; summary results of the Recurrent Coronary Prevention Project. Am Heart J. 1986;112:653-665.
171. Frasure-Smith N, Prince R. The ischemic heart disease life stress monitoring program: impact on mortality. Psychosom Med, 1985;47: 431-445.
172. Frasure-Smith N, In-hospital symptoms of psychological stress as predictors of long-term outcome after acute myocardial infarction in men. Am J Cardiol. 1991;67:121-127.
173. Frasure-Smith N, Lesperance F, Juneau M. Differential long-term impact of in-hospital symptoms of psychological stress after non-Q-wave and Q-wave myocardial infarction. Am J Cardiol. 1992;69:1128-1134.
174. Jones DA, West RR. Psychological rehabilitation after myocardial infarction: multicentre randomised controlled trial. BMJ. 1996;313:1517-1521.
175. Taylor CB, Miller NH, Smith PM, DeBusk RF. The effect of a home-based, case-managed, multifactorial risk-reduction program on reducing psychological distress in patients with cardiovascular disease. J Cardiopulm Pehabil. 1997;17: 157-162.
176. Frasure-Smith N, Lesperance F, Prince RH, Verrier P, Garber RA, Juneau M, Wolfson C, Bourassa MG. Randomised trial of homebased psychosocial nursing intervention for patients recovering from myocardial infarction, Lancet. 1997;350:473-479.
177. Muskin PR, Glassman AH. The use of tricyclic antidepressants in a medicai setting. In: Finkel JB, ed. Consuliation-Liason Psychiatry: Current Trends and Future Perspectives. New York, NY: Grune & Stratton; 1983;137-158.
178. Roose SP, Dalack GW. Treating the depressed patient with cardiovascular problems. J Clin Psychiatry. 1992;53:25-31.
179. Arana GW, Hyman SE, Handbook of Psychiatric Drug Therapy, Second Edition. Boston, Mass: Little Brown & Co; 1991:61.
180. Roose SP, Dalack GW, Glassman AH, Woodring S, Walsh T, Giardina GV. Cardiovascular effects of buproprion in depressed patients with heart disease. Am J Psychiatry, 1991b:148: 512-516.
181. Roose SP, Glassman AH, Attia E, Woodring S. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry. 1994;151: 1735-1739.
182. Roose SP, Laghrissi-Thode F, Kennedy J, Nelson C, Bigger JT Jr, Pollock B, Gafney A, Narayan M, Finkel MS, McCafferty J, Gergel I. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA. 1998;279:287-291.
183. Ellison JM, Milofsky JE, Ely E. Fluoxetineinduced bradycardia and syncope in two patients. J Clin Psychiatry. 1990;51:385-386.
184. Enemark B. The importance of EGG monitoring in antidepressant treatment. Nord J Psychiatry. 1993;47(suppl):57-65.
185. Humphries JE, Wheby MS, VandenBerg SR. Fluoxetine and the bleeding time. Arch Pathol Lab Med. 1990;114:727-728.
186. Evans TG, Buys SS, Rodgers GM. Acquired abnormalities of platelet function. N Engl J Med. 1991;324:1671.
187. Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HF. Fluoxetine and bleeding in obsessivecompulsive disorder. Am J Psychiatry. 1991;148:949.
188. Alderman CP, Moritz CK, Ben-Tovim DI. Abnormal platelet aggregation associated with fluoxetine therapy. Ann Pharmacother. 1992;26:1517-1519.
189. Callahan AM, Marangell LB, Ketter TA. Evaluating the clinical significance of drug interactions: a systematic approach. Harvard Rev Psychiatry. 1996;4:153-158.
190. Lesperance F. Erasure-Smith N, Talajic M. Major depression before and after myocardial infarction: its nature and consequences. Psychosom Med. 1996;58:99-110.
191. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
192. Musselman DL, Lewison BJ, Porter MR, Pearce BD, McDaniel JS, Miller AH, Nemeroff CB. HPA axis hyperactivity and interleukin-6 plasma concentrations in cancer patients with depression. Paper presented at: the 36th meeting of the American College of Neuropsychopharmacology; December 10, 1997; Waikoloa, Hawaii.
193. Grodstein F, Stampfer MJ, The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis. 1995;38:199-210.
194. Kon Koh K, Mincemoyer R, Bui MM, Csako G, Pucino F, Guetta V, Maclawiw M, Cannon RO. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med. 1997;336:683-690.
195. Eaker ED, Packard B, Thom TJ. Epidemiology and risk factors for coronary heart disease in women. Cardiovasc Clin. 1989;9:129-145.